...
首页> 外文期刊>Vascular pharmacology >Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications
【24h】

Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications

机译:治疗环孢菌素诱导的高血压:使用不同抗高血压药物的长期观察研究结果

获取原文
获取原文并翻译 | 示例
           

摘要

Post-transplant hypertension (PTH) is a common complication in cyclosporine immunosuppressed patients; however choosing the right antihypertensive medication is challenging. In a long-term observational study (<= 13y) we examined different antihypertensive medications on graft/patient survival of kidney recipients with pre-existing and PTH. Altogether thirty-three co-variables were analyzed including dose and type of immunosuppressive and antihypertensive medication, co-medications, serum biochemistries and the glomerular filtration rate (GFR). A Cox proportional-hazard multivariable survival model was developed to detect a Hazard Ratio (HR) of 3.0 at the Bonferroni corrected level alpha = 0.0015. Importantly, a significant relationship between immunosuppressive cyclosporine dose/serum concentration, systolic blood pressure (SBP) and GFR (p < 0.001) was observed with post-transplant hypertension being a major risk factor (HR6.1) for graft/patient survival. Although all medications lowered effectively elevated SBP the risk of graft failure/death was significantly increased when hypertension was treated with ACE inhibitors or beta-blockers (HR3.3 and 3.1) but not with angiotensin receptor- and/or Ca-channel blockers. Antihypertensive medication was associated with a decline in GFR but beta-blockers alone or in combination with ARB and/or CCB improved GFR. Neither BMI nor any of the drug combinations used in immunosuppression, i.e. prednisolone, mycophenolic acid, azathioprine and/or sirolimus influenced patient and/or graft survival while decision tree analyses informed on complex dependencies between immunosuppressive medications, dose of anti-hypertensive drug and diuretics in the management of hypertension. In conclusion, our study is suggestive for graft/patient survival to be influenced by the class of antihypertensive medication. A prospective randomized clinical trial is needed to confirm the results.
机译:移植后的高血压(PTH)是环孢菌素免疫抑制患者的常见并发症;然而,选择正确的抗高血压药物是挑战性的。在长期的观察研究(<= 13Y)中,我们在预先存在和PTH中检查了对肾脏受体的移植/患者存活的不同抗高血压药物。分析了三十三个共变量,包括剂量和免疫抑制和抗高血压药物,共同药物,血清生物化学和肾小球过滤速率(GFR)的类型。开发了一种COX比例危害多变量存活模型,以检测Bonferroni校正水平α= 0.0015的3.0的危险比(HR)。重要的是,使用后移植后高血压观察到免疫抑制环孢菌素剂量/血清浓度,收缩压(SBP)和GFR(P <0.001)之间的显着关系是移植/患者存活的主要危险因素(HR6.1)。虽然所有药物降低了有效升高的SBP,但随着ACE抑制剂或β-阻滞剂(HR3.3和3.1)处理的高血压,但没有血管紧张素受体 - 和/或CA沟道阻滞剂,虽然血管抑制剂(HR3.3和3.1)处理,但移植失败/死亡的风险显着增加。抗高血压药物与GFR的下降相关,但β-嵌体单独或与ARB和/或CCB改善GFR组合。既不是免疫抑制中使用的药物组合,即泼尼松酮,霉酚酸,偶氮嘌呤和/或西罗莫司都影响患者和/或移植物存活,而决定树分析是否在免疫抑制药物之间的复杂依赖性上,抗血血药物和利尿剂的剂量在高血压管理中。总之,我们的研究表明移植/患者生存率受到抗高血压药物类的影响。需要预期随机临床试验来确认结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号